...
首页> 外文期刊>Investigative ophthalmology & visual science >JARID1B Protein Expression and Prognostic Implications in Uveal Melanoma
【24h】

JARID1B Protein Expression and Prognostic Implications in Uveal Melanoma

机译:葡萄膜黑色素瘤中JARID1B蛋白的表达及其预后意义

获取原文
           

摘要

Purpose.: It has been suggested recently that stem cell marker expression of jumonji AT-rich interactive domain 1B (JARID1B) is required for continuous tumor growth and maintenance in human cutaneous melanoma cells. The aim of this study is to determine whether JARID1B is also expressed in uveal melanoma (UM) and whether JARID1B marks an expanded cancer stem cell pool in poor prognosis UM. Based on the available data, this is the first time JARID1B expression in UM has been studied. Methods.: A total of 121 consecutive patients diagnosed with UM and who underwent enucleation were included in the study. Immunohistochemical staining with JARID1B antibodies was performed and immunoreactivity was assessed. Correlations of JARID1B expression with established clinicopathological parameters and overall survival (OS) were evaluated in univariate and multivariate analyses. Results.: JARID1B positive expression, as defined by 0% staining, was present in 55% of UMs and invariably in ciliary body epithelium. The correlation between JARID1B negative expression and JARID1B expression 5% inside the tumor tissue and OS was borderline statistically significant based on LogRank test at 5% significance level (P = 0.06). There were significantly more JARID1B positive cells in tumors with extrascleral extension than in tumors with no or minimal intrascleral invasion (P 0.01, Mann-Whitney test). Conclusions.: This study demonstrates that JARID1B is expressed by UM cells. Despite that JARID1B was highly expressed in UM, a statistically significant association (P 0.05) between JARID1B expression and OS could not be obtained. However, a P-value of 0.06 could suggest that high JARID1B expression is correlated with lower survival; thus, a follow up study with a greater patient sample is recommended. In addition, samples of tumors characterized by high invasiveness showed a higher JARID1B expression. Furthermore, this study substantiates the presence of progenitor cells in the ciliary body epithelium.
机译:目的:最近已提出,人皮肤黑素瘤细胞中肿瘤的连续生长和维持需要富含Jumonji AT的交互式结构域1B(JARID1B)的干细胞标志物表达。这项研究的目的是确定在葡萄膜黑色素瘤(UM)中是否也表达JARID1B,以及在预后不良的UM中JARID1B是否标志着癌干细胞池的扩大。基于可用数据,这是第一次研究UM中的JARID1B表达式。方法:本研究共纳入121例连续诊断为UM并已摘除眼球的患者。进行了JARID1B抗体的免疫组织化学染色,并评估了免疫反应性。在单变量和多变量分析中评估了JARID1B表达与已建立的临床病理参数和总生存期(OS)的相关性。结果:JARID1B阳性表达(定义为> 0%染色)存在于55%的UM中,并且始终存在于睫状体上皮中。基于LogRank检验(在显着性水平为5%时),肿瘤组织和OS内部JARID1B阴性表达与JARID1B表达> 5%的相关性在统计学上具有临界统计学意义(P = 0.06)。巩膜外延伸的肿瘤中,JARID1B阳性细胞明显多于无或仅有少量巩膜内浸润的肿瘤(P <0.01,Mann-Whitney测试)。结论:这项研究证明UM细胞表达JARID1B。尽管JARID1B在UM中高度表达,但仍未获得JARID1B表达与OS之间的统计学显着关联(P <0.05)。但是,P值为0.06可能表明高JARID1B表达与较低的存活率相关。因此,建议对患者样本进行更多的随访研究。另外,以高侵袭性为特征的肿瘤样品显示出更高的JARID1B表达。此外,该研究证实了睫状体上皮中祖细胞的存在。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号